Skip to main content

Are you Dr. Ford?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 51 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Anthony Ford, MD is a board certified emergency medicine physician in Carrollton, Georgia. He is currently licensed to practice medicine in Georgia, Florida, and California. He is affiliated with Tanner Medical Center-Carrollton.

Education & Training

  • Charles R Drew University
    Charles R Drew UniversityResidency, Emergency Medicine, 1993 - 1996
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 1993

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1994 - Present
  • GA State Medical License
    GA State Medical License 1996 - 2025
  • FL State Medical License
    FL State Medical License 2005 - 2013
  • American Board of Emergency Medicine Emergency Medicine

Press Mentions

  • CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease
    CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s DiseaseNovember 9th, 2021
  • CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating That Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease
    CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating That Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative DiseaseMarch 15th, 2021
  • CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease
    CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative DiseaseSeptember 15th, 2020
  • Join now to see all

Hospital Affiliations